Meeting
2015 Gastrointestinal Cancers Symposium
A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma.
Authors
Susan Joy Littman
GI Oncology Clinic Rittenhouse Heme/Onc, Philadelphia, PA
Susan Joy Littman , Christina Brus , Ashlie Burkart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01356628
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 277)
DOI
10.1200/jco.2015.33.3_suppl.277
Abstract #
277
Poster Bd #
A48
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin
Poster
2011 ASCO Annual Meeting
The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis.
First Author: J. Chiu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line therapies in a Latino-rich cohort of US patients (pts) with hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis.
First Author: Moses Andrew Alfaro
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.
First Author: Jay Parekh